psalexa
logo

Acne Vulgaris Therapeutics Pipeline Analysis, 2017

Acne Vulgaris Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS11275
Available Format:
Pages: 141

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.3 Key Barriers

4.4 Acne Vulgaris Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Acne Vulgaris Therapeutics Pipeline Analysis by Phase (2017)

5.1 Filed: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase III: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Phase II/III: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.4 Phase II: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.5 Phase I: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.6 Pre-Clinical: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Strategic Development

5.3.4 Designation

5.3.5 Grants

5.3.6 Patent

5.3.7 Technology

5.7 Discovery: Drug profiles

5.4.1 Strategic Development

5.4.2 Designation

5.4.3 Grants

5.4.4 Patent

5.4.5 Technology

5.8 Unknown: Drug profiles

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials, by Region

6.2 Clinical Trials, by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Acne Vulgaris Therapeutics Pipeline

7.2 SWOT Analysis of Acne Vulgaris Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

TABLE 1: PIPELINE ANALYSIS OF ACNE VULGARIS BY COMPANY (2017)

TABLE 2: DESCRIPTION OF FILED

TABLE 3: CLINICAL TRIALS OF FILED

TABLE 4: DESCRIPTION OF PHASE III

TABLE 5: CLINICAL TRIALS OF PHASE III

TABLE 6: DESCRIPTION OF PHASE II/III

TABLE 7: CLINICAL TRIALS OF PHASE II/III

TABLE 8: DESCRIPTION OF PHASE II

TABLE 9: CLINICAL TRIALS OF PHASE II

TABLE 10: DESCRIPTION OF PHASE I

TABLE 11: CLINICAL TRIALS OF PHASE I

TABLE 12: DESCRIPTION OF PRE-CLINICAL

TABLE 13: DESCRIPTION OF DISCOVERY

TABLE 14: DESCRIPTION OF UNKNOWN

TABLE 15: COMPANIES - AT A GLANCE

 

 

 

LIST OF FIGURES

FIG 1: RESEARCH METHODOLOGY

FIG 2: SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3: BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 4: BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 5: NUMBER OF ACNE VULGARIS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

FIG 6: ACNE VULGARIS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

FIG 7: ACNE VULGARIS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 9: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 10: KEY PLAYERS BENCHMARKING

FIG 11: SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry